SEC Form 4 · accession 0001209191-18-038050
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eilon D. Kirson
Officer — Chief Science Officer
Period of report
Jun 13, 2018
Accepted (ET)
Jun 15, 2018 · 4:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Jun 13, 2018 | M | 30,750 | $14.37 | A | 70,332 | D | |
| Ordinary Shares | Jun 13, 2018 | M | 37,500 | $11.46 | A | 107,832 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Buy Ordinary SharesF1 | $14.37 | Jun 13, 2018 | M | 30,750 | A | — | Feb 23, 2025 | Ordinary Shares | 30,750 | 235,335 | D |
| Options to Buy Ordinary SharesF1 | $11.46 | Jun 13, 2018 | M | 37,500 | A | — | Feb 24, 2026 | Ordinary Shares | 37,500 | 37,500 | D |
Explanation of responses
- F1Options exercised were fully vested as of the date hereof.